Literature DB >> 26063318

Effect of Shenzhu Guanxin Recipe () on patients with angina pectoris after percutaneous coronary intervention: A prospective, randomized controlled trial.

Dan-Ping Xu1, Huan-Lin Wu, Tao-Hua Lan, Xia Wang, Xiao-Gang Sheng, Yu Lin, Song Li, Chao-Yang Zheng.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of a combination therapy using Chinese medicine (CM) Shenzhu Guanxin Recipe (, SGR) and standard Western medicine treatment (SWMT) in patients with angina pectoris after percutaneous coronary intervention (PCI).
METHODS: Double-blind randomized controlled trial was used in this experimental procedure. One hundred and eighty-seven patients with coronary heart disease receiving SWMT after PCI were randomly assigned to the treatment (SGR) and control (placebo) groups. Outcome measures including angina pectoris score (APS), CM symptom score, and Seattle Angina Questionnaire (SAQ) score were evaluated in 1, 2, 3 and 12 months, and the death rate, restenosis and other emergency treatments were observed. The mixed-effects models were employed for the data analysis.
RESULTS: In the treatment group, a larger within-treatment effect size (d=1.74) was found, with a 76.7% reduction in APS from pretreatment to 12-month follow-up assessment compared with the control group (d=0.83, 53.8% symptom reduction); betweentreatment (BT) effect size was d=0.66. CM symptom scores included an 18.3% reduction in the treatment group (d=0.46), and a 16.1% decrease in the control group (d=0.31); d=0.62 for BT effect size. In regard to scores of SAQ, the BT effect size of cognition level of disease was larger in the treatment group (d=0.63), followed by the level of body limitation of activity (d=0.62), condition of angina pectoris attacks (d=0.55), satisfaction level of treatments (d=0.31), and steady state of angina pectoris (d=0.30). Two cardiovascular related deaths and one incidental death were recorded in the control and treatment groups, respectively. No significant difference in any cardiovascular event (including death toll, frequency of cardiovascular hospitalization or emergency room visits) was found between the two groups.
CONCLUSION: The combination therapy of SGR and SWMT is effective and safe in patients with angina pectoris after PCI when compared with SWMT alone.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26063318     DOI: 10.1007/s11655-015-2040-6

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  24 in total

1.  [Clinical study on effect of concentrated xuefu zhuyu pill on restenosis of 43 cases coronary heart disease after intracoronary stenting].

Authors:  B Yu; K Chen; J Mao
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  1998-10

2.  AHA statement highlights gender differences in PCI: part II.

Authors:  Jennifer White
Journal:  J Interv Cardiol       Date:  2005-10       Impact factor: 2.279

3.  [Trial study on DENG Tie-tao's coronary heart disease capsules in improving patients' quality of life].

Authors:  Huan-lin Wu; Xia Wang; Xin-mei Li; Wen-jie Luo; Tie-tao Deng
Journal:  Chin J Integr Med       Date:  2005-09       Impact factor: 1.978

4.  Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial.

Authors:  Uwe Zeymer; Hans-Richard Arntz; Bernd Mark; Stephan Fichtlscherer; Gerald Werner; Ralph Schöller; Ralf Zahn; Frank Diller; Harald Darius; Thorsten Dill; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2011-12-21       Impact factor: 5.460

5.  A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients.

Authors:  Qing-hua Shang; Hao Xu; Xiao-yan Lu; Chuan Wen; Da-zhuo Shi; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2011-09-11       Impact factor: 1.978

6.  [Effect of shuxuetong in preventing restenosis after intracoronary stenting].

Authors:  Ai-hua Li; Kai-zheng Gong; Jun-feng Yan; Xiaoning Sun; Yiliang Feng; Zhengang Zhang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2004-10

7.  Monitoring the quality of life in patients with coronary artery disease.

Authors:  J A Spertus; J A Winder; T A Dewhurst; R A Deyo; S D Fihn
Journal:  Am J Cardiol       Date:  1994-12-15       Impact factor: 2.778

8.  Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

Authors:  Yaling Han; Yi Li; Shouli Wang; Quanmin Jing; Zhulu Wang; Dongmei Wang; Qingfen Shu; Xiuying Tang
Journal:  Am Heart J       Date:  2009-03-17       Impact factor: 4.749

9.  Clinical and Epidemiological Investigation of TCM Syndromes of Patients with Coronary Heart Disease in China.

Authors:  Yi Ren; Minzhou Zhang; Keji Chen; Shijie You; Jianjun Li; Liheng Guo; Lei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-03-22       Impact factor: 2.629

Review 10.  Getting with the ACC/AHA guidelines for the treatment of chronic angina as a disease state.

Authors:  Prakash C Deedwania; Enrique V Carbajal
Journal:  Rev Cardiovasc Med       Date:  2009       Impact factor: 2.930

View more
  7 in total

1.  Shenzhu Guanxin Recipe Granules () for Improving Exercise Tolerance in Patients with Stable Angina (SERIES Trial): A Protocol of Multicenter, Randomized, Double-Blind, Placebo Parallel Controlled Clinical Trial.

Authors:  Shuai Mao; Dan-Ping Xu; Xiao-Jing Dang; Winny Li; Huan-Lin Wu
Journal:  Chin J Integr Med       Date:  2018-10-17       Impact factor: 1.978

2.  Identification of human serum protein targets of Qianggu Decoction () in primary type I osteoporosis based on tandem mass tag labeling and liquid chromatography-tandem mass spectrometry technology.

Authors:  Bo-Cheng Liang; Xiao-Lin Shi; Chun-Wen Li; Zhen-Yu Shi; Wei-Tao He; Jian-Liang Yao; Ling-Cheng Kong; Xu-Yun Li
Journal:  Chin J Integr Med       Date:  2016-07-07       Impact factor: 1.978

3.  Traditional Chinese Medicine ShenZhuGuanXin Granules Mitigate Cardiac Dysfunction and Promote Myocardium Angiogenesis in Myocardial Infarction Rats by Upregulating PECAM-1/CD31 and VEGF Expression.

Authors:  Dan-Ping Xu; De-Zhi Zou; Hui-Liang Qiu; Huan-Lin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-03       Impact factor: 2.629

4.  Traditional Chinese Medicine for Coronary Heart Disease: Clinical Evidence and Possible Mechanisms.

Authors:  Ke-Jian Zhang; Qun Zheng; Peng-Chong Zhu; Qiang Tong; Zhuang Zhuang; Jia-Zhen Zhu; Xiao-Yi Bao; Yue-Yue Huang; Guo-Qing Zheng; Yan Wang
Journal:  Front Pharmacol       Date:  2019-08-02       Impact factor: 5.810

5.  The efficacy and safety of Shenzhu Guanxin Recipe Granules for the treatment of patients with coronary artery disease: protocol for a double-blind, randomized controlled trial.

Authors:  Xiao Jin; Biqi Pan; Huanlin Wu; Bingxin Wu; Yukai Li; Xia Wang; Guoqing Liu; Xiaojing Dang; Danping Xu
Journal:  Trials       Date:  2019-08-20       Impact factor: 2.279

Review 6.  Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases.

Authors:  Xi Guo; Xiaojun Chen; Jinlan Chen; Zhiping Tan; Yifeng Yang; Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-12       Impact factor: 2.629

7.  Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial.

Authors:  Yu Wang; Yuhan Xu; Ling Zhang; Shuwei Huang; Liping Dou; Jiehong Yang; Wei Fu; Peng Zhou; Haitong Wan
Journal:  Trials       Date:  2022-01-21       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.